Interleukin-2 inhibits polarization to T helper type 1 cells and prevents mouse acute graft-versus-host disease through up-regulating suppressors of cytokine signalling-3 expression of naive CD4+ T cells

Clinical and Experimental Immunology

Volumn 160, Issue 3, 2010, Pages 479-488

  Zhao, J ^a,b   Zhang, T ^a,c   He, H ^a   Xie, Y ^a  

^a FUDAN UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

Acute graft versus host disease; IL 2; Suppressors of cytokine signalling (SOCS) 3; T helper 1 cell; T helper 2 cell

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MESSENGER RNA; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; UPREGULATION;

ACUTE DISEASE; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; FEMALE; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; INTERLEUKIN-2; ISOANTIGENS; JANUS KINASES; MALE; MICE; MICE, INBRED BALB C; RNA, MESSENGER; STAT TRANSCRIPTION FACTORS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TH1 CELLS;

EID: 77952199811     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04089.x     Document Type: Article

References (42)

1. Appelbaum FR. Hematopoietic cell transplantation as immunotherapy. Nature 2001 411 : 385 389.
2. Kolb HJ, Mittermüller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990 76 : 2462 2465.
3. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004 103 : 767 766. (Pubitemid 38129531)
4. Anderson BE, McNiff J, Yan J et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003 112 : 101 108. (Pubitemid 38056381)
5. Zhang Y, Joe G, Zhu J et al. Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood 2004 103 : 3970 3978. (Pubitemid 38596321)
6. Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999 285 : 412 415. (Pubitemid 29343964)
7. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992 80 : 2964 2968.
8. Teshima T, Ordemann R, Reddy P et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002 8 : 575 581. (Pubitemid 34633434)
9. Zorn E, Wang KS, Hochberg EP et al. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 2002 8 : 2052 2060. (Pubitemid 34753573)
10. Rissoan MC, Soumelis V, Kadowaki N et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999 283 : 1183 1186. (Pubitemid 129504124)
11. Rossi M, Arpinati M, Rondelli D, Anasetti C. Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation? Hum Immunol 2002 63 : 1194 1200. (Pubitemid 36025994)
12. Arpinati M, Chirumbolo G, Urbini B, Perrone G, Rondelli D, Anasetti C. Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2003 11 : 345 356. (Pubitemid 37120553)
13. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signaling and immune regulation. Nat Rev Immunol 2007 7 : 454 465. (Pubitemid 46834848)
14. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002 2 : 1 7.
15. Egwuagu CE, Yu CR, Zhang M, Mahdi RM, Kim SJ, Gery I. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J Immunol 2002 168 : 3181 3187. (Pubitemid 34250377)
16. Yu CR, Mahdi RM, Ebong S, Vistica BP, Gery I, Egwuagu CE. Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. J Biol Chem 2003 278 : 29752 29759. (Pubitemid 36962361)
17. Chong MM, Cornish AL, Darwiche R et al. Suppressor of cytokine signaling-1 is a critical regulator of interleukin-7-dependent CD8+ T cell differentiation. Immunity 2003 18 : 475 487. (Pubitemid 36513630)
18. Cornish AL, Davey GM, Metcalf D et al. Suppressor of cytokine signaling-1 has IFN-gamma-independent actions in T cell homeostasis. J Immunol 2003 170 : 878 886. (Pubitemid 36070541)
19. Fletcher J, Starr R. The role of suppressors of cytokine signaling in thymopoiesis and T cell activation. Int J Biochem Cell Biol 2005 37 : 1774 1786. (Pubitemid 40961663)
20. Fujimoto M, Tsutsui H, Yumikura-Futatsugi S et al. A regulatory role for suppressor of cytokine signaling-1 in Th polarization in vivo. Int Immunol 2002 14 : 1343 1350. (Pubitemid 35331431)
21. Seki Y, Inoue H, Nagata N et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med 2003 9 : 1047 1054. (Pubitemid 37021785)
22. Cohney SJ, Sanden D, Cacalano NA et al. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol 1999 19 : 4980 4988. (Pubitemid 29289537)
23. Matsumoto A, Seki Y, Watanabe R et al. A role of suppressor of cytokine signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated interleukin 2 production. J Exp Med 2003 197 : 425 436. (Pubitemid 36278599)
24. Brender C, Tannahill GM, Jenkins BJ et al. Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 27. Blood 2007 110 : 2528 2536. (Pubitemid 47523175)
25. Endo TA, Masuhara M, Yokouchi M et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997 387 : 921 924. (Pubitemid 27289595)
26. Starr R, Willson TA, Viney EM et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997 387 : 917 921. (Pubitemid 27289594)
27. Hilton DJ. Negative regulators of cytokine signal transduction. Cell Mol Life Sci 1999 55 : 1568 1577. (Pubitemid 29445822)
28. Egwuagu CE, Sztein J, Mahdi RM et al. IFN-gamma increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats. J Immunol 1999 162 : 510 517. (Pubitemid 29018961)
29. Kim SJ, Zhang M, Vistica BP et al. Induction of ocular inflammation by T-helper lymphocytes Type 2. Invest Ophthalmol Vis Sci 2002 43 : 758 765. (Pubitemid 34184494)
30. Yoshimoto TM, Furuhata M, Kamiya S et al. Positive modulation of IL-12 signaling by sphingosine kinase 2 associating with the IL-12 receptor beta 1 cytoplasmic region. J Immunol 2003 171 : 1352 1359. (Pubitemid 36900067)
31. Ji YH, Weiss L, Zeira M et al. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses. Bone Marrow Transplant 2003 32 : 495 504. (Pubitemid 37160965)
32. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood 2006 107 : 1564 1569. (Pubitemid 43242395)
33. Cooke KR, Kobzik L, Martin TR et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996 88 : 3230 3239. (Pubitemid 26357409)
34. Hill GR, Cooke KR, Teshima T et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998 102 : 115 123. (Pubitemid 28323837)
35. Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004 101 : 1936 1946. (Pubitemid 39425368)
36. Morris ES, Hill GR. Advances in the understanding of acute graft-versus-host disease. Br J Haematol 2007 137 : 3 19. (Pubitemid 46426400)
37. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988 240 : 1169.
38. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Huntingt) 2002 16 : 4.
39. Pahwa S, Morales M. Interleukin-2 therapy in HIV infection. AIDS Patient Care STDS 1998 12 : 187. (Pubitemid 28150908)
40. Morris JC, Waldmann TA. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 2000 59 : i109.
41. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol 2004 172 : 3983 3988.
42. Sykes M, Harty MW, Szot GL, Pearson DA. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4+ and CD8+-mediated graft-versus-leukemia effects. Blood 1994 83 : 2560 2569. (Pubitemid 24135848)